Table 4. Comparison of clinical and angiogenesis factors according to treatment type of rheumatoid arthritis patients (n=40).

	Mean±SD	Min-Max	Mean±SD	Min-Max	Mean±SD	Min-Max	P
Duration of morning stiffness	60.0±62.3	10-180	33.0±46.7	0-120	10.0±18.6	0-60	0.026
Number of swollen joints	8.7±5.1	1-15	2.9±3.2	0-10	3.9±3.7	0-10	0.038
Number of sensitive joints	14.5±7.9	1-21	10.8±8.3	1-27	13.1±8.9	0-26	0.529
General assessment of patient condition	5.8±1.2	4-7	3.6±1.8	1-7	4.3±2.1	1-7	0.041
General assessment by the physician	5.7±1.0	4-7	3.5±1.8	1-6	4.2±2.1	1-7	0.033
Pain assessment of the patient	5.7±1.2	4-7	3.7±1.9	1-7.5	4.5±1.9	1-7	0.072
DAS28 score	6.1±1.3	4.06-7.48	4.7±1.2	2.72-7.24	5.0±1.5	2.64-6.89	0.102
Ritchie score	17.0±7.1	5-26	10.2±5.2	3-23	10.9±5.5	2-17	0.067
HAQ score	0.9±0.5	0.25-1.62	0.6±0.57	0-2	0.6±0.4	0-1.37	0.429
VEGF (pg/mL)	387.3±319.7	162.52-926.21	586.9±354.5	120.39-1460	476.0±232.6	93.36-892.31	0.341
ANG1 (pg/mL)	55032.0±15531.2	40372.25-80179.12	66097.4±21212.0	24398.63-115656.58	55579.0±14354.4	36412.78-81210.54	0.119
ANG2 (pg/mL)	3696.3±1255.4	2453.56-5723.26	4384.5±1388.08	1584.82-7094.11	3630.9±1063.6	2169.10-5519.82	0.181
Tie-2 (ng/mL)	32.8±7.5	24.10-41.12	32.8±11.6	15.70-58.03	27.9±5.3	18-35.41G	0.427
SD: Standard deviation; Min: Minimum; Max: Maximum; DAS28: Disease activity score 28; HAQ: Health assessment questionnaire; VEGF: Vascular endothelial growth factor; ANG: Angiopoietin; Tie-2: Tyrosine-protein kinase receptor for angiopoietin; Kruskal-Wallis test was used.